LOGIN  |  REGISTER
Chimerix
Compass Therapeutics

Perrigo to Attend Upcoming Consumer Investor Conferences

October 31, 2023 | Last Trade: US$25.44 0.75 -2.86

DUBLIN, Oct. 31, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO, Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to participate in one-on-one investor meetings at the Jefferies Consumer Conference in Miami, FL on Wednesday, November 15th, 2023.

Separately, President and CEO, Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Morgan Stanley Consumer & Retail Conference in New York City on Wednesday, December 6th, 2023, at 1:30 PM EST.   

Interested parties can access the Morgan Stanley webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts.

About Perrigo 

Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at www.perrigo.com

Forward-Looking Statements

This press release includes, and the matters discussed in Perrigo's investor meetings at the Jefferies Consumer Conference and the Morgan Stanley Consumer & Retail Conference will include certain "forward-looking statements" within the meaning of the Private Litigation Securities Reform Act of 1995, as amended. Forward-looking statements relate to future events and involve known and unknown risks, uncertainties and other factors—many of which beyond the Company's control—that may cause the actual results, performance or achievements of the Company to be materially different from its current expectations, assumptions, estimates and projections. Interested persons are urged to consult the Company's filings with the United States Securities and Exchange Commission, available at https://investor.perrigo.com/sec-filings, for a discussion of the Company's business and financial condition and certain material trends, risks, uncertainties and other factors relating thereto, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2022.

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB